PWMG
STOK icon

Prestige Wealth Management Group’s Stoke Therapeutics STOK Stock Holding History

Prestige Wealth Management Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.54K Hold
200
– – ﹤0.01% 518
2026
Q1 		$6.51K Hold
200
– – ﹤0.01% 502
2025
Q4 		$6.35K Buy
+200
New +$6.01K ﹤0.01% 526

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Prestige Wealth Management Group's STOK Position: Q2 2026 in Review

Prestige Wealth Management Group held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 200 shares worth $6.54K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

Prestige Wealth Management Group first reported a position in STOK in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Prestige Wealth Management Group held 200 shares of Stoke Therapeutics worth $6.54K as of Q2 2026.
  • Prestige Wealth Management Group left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #518 holding.
  • Prestige Wealth Management Group first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.